BFA
BLPH

BlackRock Fund Advisors’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

BlackRock Fund Advisors’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-614
Closed -$23K – 4346
2016
Q1 		$23K Sell
614
-60
-9% -$2.22K ﹤0.01% 3891
2015
Q4 		$30K Buy
+674
New +$32.6K ﹤0.01% 3933

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
GA
Geneva Advisors Chicago, Illinois $5.81B AUM 23.71% 1-Year Est. Return

BlackRock Fund Advisors's BLPH Position: Q2 2016 in Review

BlackRock Fund Advisors sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2016, closing a stake of 614 shares — an estimated $23K sold.

BlackRock Fund Advisors first reported a position in BLPH in Q4 2015 and held it in 2 quarters. The position peaked at $30K in Q4 2015. 17 funds tracked by Wall St. Rank hold BLPH as of Q2 2016.

  • BlackRock Fund Advisors reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • BlackRock Fund Advisors sold 614 Bellerophon Therapeutics, Inc. shares in Q2 2016, an estimated $23K.
  • BlackRock Fund Advisors first reported a position in Bellerophon Therapeutics, Inc. in Q4 2015 and held it in 2 quarters.
  • BlackRock Fund Advisors's Bellerophon Therapeutics, Inc. position peaked at $30K in Q4 2015.
  • 17 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2016.

Based on BlackRock Fund Advisors's 13F filing for Q2 2016, filed 10 Aug 2016.